Product Pipeline

This list contains information about the development status of unapproved drugs or unapproved indications. Nothing herein are intended to constitute promotion or advertisement of pharmaceutical products (including products currently in development).

IND Code

 Dosage Form Features Indications Development Locations Development Stage
TAS-116 Oral HSP90 inhibitor
Solid tumors US Phase I
Europe Phase I
Prostate cancer Japan Phase II
TAS-117 Oral AKT inhibitor Solid tumors with germline PTEN mutations Japan Phase II
US Phase II
Europe Phase II
TAS0728 Oral 　 Solid tumors US Phase I/II
Europe Phase I/II
TAS0953 Oral RET inhibitor Solid tumors Japan Phase I/II
Cancer cachexia Japan Phase II
TAS3351 Oral Non-small cell lung cancer Japan Phase I/II
US Phase I/II
Europe Phase I/II
TAS6417 Oral EGFR inhibitor Non-small cell lung cancer US Filed
Japan Phase III
US Phase III
Europe Phase III
TAS6417 + SCC244 Oral EGFR inhibitor + MET inhibitor Non-small cell lung cancer Japan Phase I
TAS6417 + TAS-116 Oral EGFR inhibitor + HSP90 inhibitor Non-small cell lung cancer Japan Phase I
TAS6417 + AB680 Oral + Injection EGFR inhibitor + CD73 inhibitor Non-small cell lung cancer Japan Phase I
ET-743 Injection Ovarian cancer Japan Phase I
ARC-02 Injection Non-hodgkin lymphoma US Phase I
AB122 Injection Anti-PD-1 antibody Solid tumors Japan Phase I
AB122 + TAS-116 Injection + Oral Anti-PD-1 antibody + HSP90 inhibitor Solid tumors Japan Phase I
AB122 + TAS-120 Injection + Oral Anti-PD-1 antibody + FGFR inhibitor Biliary tract cancer Japan Phase III
AB122 + AB154 Injection Anti-PD-1 antibody + anti-TIGIT antibody Upper gastrointestinal tract cancer Japan Phase III
Non-small cell lung cancer Japan Phase III
AB521 Oral HIF-2α inhibitor Renal cell carcinoma Japan Phase III

AB680 + ABI-007

 Injection CD73 inhibitor＋microtubule inhibitor (nanoparticle) Pancreatic ductal adenocarcinoma Japan Phase III
ASTX727 Oral DNA methyltransferase inhibitor Myelodysplastic syndromes Japan Phase I
China Phase I/II
ASTX660 Oral IAP inhibitor T-cell lymphoma Japan Phase I
ASTX660 + ASTX727 Oral T-cell lymphoma US Phase I
ASTX030 Oral DNA methyltransferase inhibitor Myelodysplastic syndromes Japan Phase I
Myelodysplastic syndromes, Chronic Myelomonocytic Leukemia, Acute myeloid leukemia US Phase III
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy (DMD) Japan Phase III
TAS5315 Oral BTK inhibitor Rheumatoid arthritis (RA) Japan Phase II
Chronic spontaneous urticaria Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with overactive bladder Japan Phase II

As of Sep. 30, 2026